<DOC>
	<DOC>NCT02149875</DOC>
	<brief_summary>The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.</brief_summary>
	<brief_title>Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>3-n-butylphthalide</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Acute ischemic stroke within 12 hours for the first time before entry into the study National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25 with lacunar infarction with cerebral hemorrhagic infarction with epilepsy or epileptic persons with history of neurological diseases with myocardial infarction, with renal and hepatic abnormalities with metabolic diseases with contraindications to antiplatelet treatments</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Dl-3-n-butylphthalide</keyword>
	<keyword>Cerebrolysin</keyword>
</DOC>